Patient Characteristics and Elranatamab administration patterns of Real-World Patients Receiving Elranatamab

Study identification

• EU PAS number:
  EUPAS1000000853
• Study ID:
  1000000853
• Official title and acronym:
  Patient Characteristics and Elranatamab administration patterns of Real-World Patients Receiving Elranatamab
• DARWIN EU® study:
  No
• Study countries:
  United States
• Study description:
  No information provided.
• Study status:
  Planned

Research institutions and networks

No information provided.

Study timelines

Date when funding contract was signed

Planned:31/07/2025

Actual:31/07/2025

Study start date

Planned:27/03/2026

Date of final study report

Planned:01/04/2027

Sources of funding

More details on funding

No information provided.

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable